NasdaqGS:UTHRBiotechs
Positive miroliverELAP Phase 1 Data Could Be A Game Changer For United Therapeutics (UTHR)
United Therapeutics recently reported positive phase 1 results for miroliverELAP, an investigational external liver assist device tested in five acute liver failure patients who were not transplant candidates, with survival achieved during treatment and no unexpected serious adverse events over 32 days of follow-up.
This early success underscores the company’s broader push into bioengineered organ alternatives, potentially expanding its role beyond pulmonary disease into life-support...